tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ernst A et al. Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. 1998 Transplantation pmid:9448158
Levy G et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. 2004 Transplantation pmid:15201658
O'Grady J C(2) monitoring: out of the blocks but with some way to go! 2004 Transplantation pmid:15201659
Ajiki T et al. Generation of donor hematolymphoid cells after rat-limb composite grafting. 2003 Transplantation pmid:12640301
Tsuchiya N et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. 2004 Transplantation pmid:15502717
Josephson MA et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. 2004 Transplantation pmid:15502727
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
van Hooff JP et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. 2003 Transplantation pmid:12829890
Donnadieu B et al. Central retinal vein occlusion-associated tacrolimus after liver transplantation. 2014 Transplantation pmid:25955343
Vacher-Coponat H et al. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. 2006 Transplantation pmid:16926601
Ciancio G et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. 2011 Transplantation pmid:22027927
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Starzl TE et al. Hepatotrophic effects of FK506 in dogs. 1991 Transplantation pmid:1702912
Prud'homme GJ et al. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. 2013 Transplantation pmid:23851932
Nashan B et al. Clinical validation studies of Neoral C(2) monitoring: a review. 2002 Transplantation pmid:12023607
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Ekberg H et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. 2009 Transplantation pmid:19424036
Mestres J et al. Late subcapsular lymphocele in a kidney graft. 2012 Transplantation pmid:22487814
Jain A et al. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. 2001 Transplantation pmid:11374410
Cherikh WS et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. 2003 Transplantation pmid:14627905
Ahsan N et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. 2001 Transplantation pmid:11477347
Chapman WC et al. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. 2017 Transplantation pmid:28121741
Sommerer C et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. 2010 Transplantation pmid:20463649
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Becker T et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. 2008 Transplantation pmid:19104406
Froud T et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. 2008 Transplantation pmid:19104407
Yamani MH et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. 2000 Transplantation pmid:10868634
Verleden GM et al. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. 2002 Transplantation pmid:12131703
Borni-Duval C et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. 2013 Transplantation pmid:23778568
Johnson C et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. 2000 Transplantation pmid:10755536
Ekser B et al. Hepatic function after genetically engineered pig liver transplantation in baboons. 2010 Transplantation pmid:20606605
Ochiai T et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. 1987 Transplantation pmid:2447689
Jain A et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. 2005 Transplantation pmid:16210976
Mourer JS et al. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. 2012 Transplantation pmid:22955227
Florman S et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. 2007 Transplantation pmid:17589349
Alloway R et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. 2007 Transplantation pmid:17589351
Dieterle CD et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. 2004 Transplantation pmid:15239622
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Aptaramanov B et al. A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment. 2011 Transplant. Proc. pmid:21486609
Ma A et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates. 2005 Jan-Feb Transplant. Proc. pmid:15808578
Platz KP et al. FK506 for primary and rescue therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636570
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
Serrano M et al. Clinical value of a single determination of intracellular ATP levels in stimulated CD4+ T lymphocytes in pediatric patients with stable liver transplantation. 2012 Transplant. Proc. pmid:23146475
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Liu M et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. 2004 Transplant. Proc. pmid:15518760
Stratta RJ Late acute rejection episodes after vascularized pancreas transplantation. 1998 Transplant. Proc. pmid:9636633
Demirbas A et al. FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. 1997 Transplant. Proc. pmid:9365608
Marente VC et al. Modigraf administration through jejunostomy in liver transplant recipient: case report. 2013 Transplant. Proc. pmid:24314992
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Ziolkowski J et al. Effect of immunosuppressive regimen on acute rejection and liver graft function. 2003 Transplant. Proc. pmid:14529915
Kato T et al. FK506 may suppress liver injury during the early period following living-related liver transplantation. 2003 Transplant. Proc. pmid:12591316
Bahra M et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. 2005 Transplant. Proc. pmid:15919436
Maes BD and Vanrenterghem YF Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. 2004 Transplant. Proc. pmid:15041305
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Waller JR et al. Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. 2002 Transplant. Proc. pmid:12176449
Malireddy SR et al. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. 2008 Transplant. Proc. pmid:18589198
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Nanni G et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosupression. 2002 Transplant. Proc. pmid:12270323
Malaise J et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182827
Endoh M et al. Nonmuscle myosin heavy chain and metalloproteinase-2 expression in concordant pulmonary xenografts. 2000 Transplant. Proc. pmid:10936397
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Han DJ et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. 2012 Transplant. Proc. pmid:22310592
Chang HR et al. Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients. 2007 Transplant. Proc. pmid:17580178
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Iacona I et al. Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123489
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Fábrega E et al. Effect of immunosuppressant blood levels on serum concentration of interleukin-17 and -23 in stable liver transplant recipients. 2009 Transplant. Proc. pmid:19376417
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Burke GW et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. 2002 Transplant. Proc. pmid:12176628
Aguirrezabalaga J et al. Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. 2001 Feb-Mar Transplant. Proc. pmid:11267192
Kovarik JM et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. 2006 Transplant. Proc. pmid:17175302
Moura Neto A et al. Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. 2018 Transplant. Proc. pmid:29661438
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Banerjee R et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267435
Abe T et al. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. 2014 Transplant. Proc. pmid:24767367
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Bresci S et al. Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu. 2010 Jul-Aug Transplant. Proc. pmid:20692461
Ott R et al. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750359
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509